+

PE20250776A1 - Sales y formas solidas de un inhibidor de fgfr y procesos para su preparacion - Google Patents

Sales y formas solidas de un inhibidor de fgfr y procesos para su preparacion

Info

Publication number
PE20250776A1
PE20250776A1 PE2024001456A PE2024001456A PE20250776A1 PE 20250776 A1 PE20250776 A1 PE 20250776A1 PE 2024001456 A PE2024001456 A PE 2024001456A PE 2024001456 A PE2024001456 A PE 2024001456A PE 20250776 A1 PE20250776 A1 PE 20250776A1
Authority
PE
Peru
Prior art keywords
salts
preparation
solid forms
processes
fgfr inhibitor
Prior art date
Application number
PE2024001456A
Other languages
English (en)
Inventor
Pingli Liu
Zhongjiang Jia
Qiyan Lin
Naijing Su
Timothy Martin
Michael Xia
Jiacheng Zhou
Baoyu Mi
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of PE20250776A1 publication Critical patent/PE20250776A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a sales y formas solidas del inhibidor de FGFR (7R,8aS)-2-(5-(5-(2,3-dimetilfenil)-6-metoxi-1H-pirazolo[4,3-b]piridin-3-il)piridin-2-il)octahidropirrolo[1,2-a]pirazin-7-ol, e incluye metodos para su preparacion, en donde los compuestos, las sales y las formas solidas son utiles en el tratamiento de enfermedades mediadas por FGFR, tales como el cancer. En particular, hace referencia a una forma solida del Compuesto 1 con la formula (I) en donde la forma solida es cristalina.
PE2024001456A 2021-12-22 2022-12-21 Sales y formas solidas de un inhibidor de fgfr y procesos para su preparacion PE20250776A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163292628P 2021-12-22 2021-12-22
PCT/US2022/053582 WO2023122134A1 (en) 2021-12-22 2022-12-21 Salts and solid forms of an fgfr inhibitor and processes of preparing thereof

Publications (1)

Publication Number Publication Date
PE20250776A1 true PE20250776A1 (es) 2025-03-14

Family

ID=85172903

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024001456A PE20250776A1 (es) 2021-12-22 2022-12-21 Sales y formas solidas de un inhibidor de fgfr y procesos para su preparacion

Country Status (15)

Country Link
US (1) US20230192722A1 (es)
EP (1) EP4452982A1 (es)
JP (1) JP2025500466A (es)
KR (1) KR20240136984A (es)
CN (1) CN118660889A (es)
AR (1) AR128043A1 (es)
AU (1) AU2022418585A1 (es)
CL (1) CL2024001873A1 (es)
CO (1) CO2024009568A2 (es)
CR (1) CR20240297A (es)
IL (1) IL313735A (es)
MX (1) MX2024007951A (es)
PE (1) PE20250776A1 (es)
TW (1) TW202340215A (es)
WO (1) WO2023122134A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20230467A (es) 2021-03-10 2024-02-20 Jnana Therapeutics Inc Inhibidores de molécula pequeña de la función de slc6a19 de mamífero

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
AU5620299A (en) 1998-08-11 2000-03-06 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
ES2225624T3 (es) 2000-06-28 2005-03-16 Smithkline Beecham Plc Procedimiento de molienda por via humeda.
WO2003024967A2 (en) 2001-09-19 2003-03-27 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
CA2462657C (en) 2001-10-30 2011-04-26 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
WO2003062236A1 (en) 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
CN101106983A (zh) 2004-11-24 2008-01-16 诺瓦提斯公司 JAK抑制剂与至少一种Bcr-Abl、Flt-3、FAK或RAF激酶抑制剂的组合
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
CA2709202C (en) 2007-12-19 2013-04-23 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EP3530672B1 (en) 2008-09-26 2024-05-01 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
RU2017132160A (ru) 2008-12-09 2019-02-08 Дженентек, Инк. Антитела к pd-l1 и их применение для усиления функции t-клеток
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
HRP20161092T1 (hr) 2010-10-25 2016-10-21 G1 Therapeutics, Inc. Cdk inhibitori
MY161199A (en) 2011-03-23 2017-04-14 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
HUE056201T2 (hu) 2015-07-30 2022-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
DK3377488T3 (da) 2015-11-19 2022-10-03 Incyte Corp Heterocykliske forbindelser som immunomodulatorer
WO2017106634A1 (en) 2015-12-17 2017-06-22 Incyte Corporation N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators
HUE052722T2 (hu) 2015-12-22 2021-05-28 Incyte Corp Heterociklusos vegyületek mint immunomodulátorok
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
TW201808902A (zh) 2016-05-26 2018-03-16 美商英塞特公司 作為免疫調節劑之雜環化合物
EP3472167B1 (en) 2016-06-20 2022-08-03 Incyte Corporation Heterocyclic compounds as immunomodulators
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
MX391980B (es) 2016-12-22 2025-03-21 Incyte Corp Derivados de tetrahidro imidazo [4,5-c] piridina como inductores de internalización de ligando 1 de muerte programada (pd-l1).
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
MX391981B (es) 2016-12-22 2025-03-21 Incyte Corp Derivados de benzooxazol como inmunomoduladores.
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
UA128453C2 (uk) 2018-03-30 2024-07-17 Інсайт Корпорейшн Гетероциклічні сполуки як імуномодулятори
HRP20230306T1 (hr) 2018-05-11 2023-05-12 Incyte Corporation Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors

Also Published As

Publication number Publication date
TW202340215A (zh) 2023-10-16
AU2022418585A1 (en) 2024-07-11
MX2024007951A (es) 2024-07-10
EP4452982A1 (en) 2024-10-30
AR128043A1 (es) 2024-03-20
CN118660889A (zh) 2024-09-17
US20230192722A1 (en) 2023-06-22
WO2023122134A1 (en) 2023-06-29
CO2024009568A2 (es) 2024-07-29
JP2025500466A (ja) 2025-01-09
CR20240297A (es) 2024-09-18
KR20240136984A (ko) 2024-09-19
IL313735A (en) 2024-08-01
CL2024001873A1 (es) 2024-12-06

Similar Documents

Publication Publication Date Title
PE20250776A1 (es) Sales y formas solidas de un inhibidor de fgfr y procesos para su preparacion
CU20210015A7 (es) COMPUESTOS DE PIRAZOLO [3.4-b] PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET
CO2019004123A2 (es) Proceso para la preparacion de pirazolo[1,5-a]pirimidinas y sales de estas
AR112828A1 (es) Proceso para la preparación de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-(2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4-ona
MX2018014871A (es) Proceso de preparacion de n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4, 5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida .
UY35935A (es) Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4
PE20171104A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2018003264A1 (es) Procesos para la preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo.
NI201600166A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso para tratar cáncer
PE20170663A1 (es) Compuestos de 5- cloro- 2- difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
MX2018008131A (es) Forma cristalina del inhibidor de la btk quinasa y metodo de preparacion de la misma.
MY200629A (en) Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
MX2017006412A (es) Forma cristalina de sulfato acido de (s)-n-(5-((r)-2-(2,5-difluoro fenil)-pirrolidin-1-il)-pirazolo[1,5-a]-pirimidin-3-il)-3-hidroxi pirrolidina-1-carboxamida.
PE20210002A1 (es) Sales de derivados de pirrolotriazina utiles como inhibidores tam
PE20121150A1 (es) Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer
PE20152033A1 (es) Heterociclos bicicliclos como inhibidores de fgfr
MX2015009950A (es) Compuestos de imidazopiridina y sus usos.
PE20210658A1 (es) Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat)
MX2021004487A (es) Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion.
AR119210A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
PE20140864A1 (es) COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA COMO INHIBIDOR DE PI3K/mTOR
MX2017009270A (es) Hidroxietil sulfonato de inhibidor de proteina cinasa dependiente de ciclina, su forma cristalina y su metodo de preparacion.
CL2016000496A1 (es) Compuestos derivados de 1,2,4-triazolo[1,5-a]-piridina, inhibidores de una janus cinasa, tal como jak1; composiciones farmacológicas; útiles para el tratamiento de enfermedades inflamatorias.
CO2023007677A2 (es) Derivados de pyrazolo[1,5-a]pirazina como inhibidores de la btk
PE20200932A1 (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载